<scp>COVID</scp>‐19 vaccine and pregnancy outcomes: A systematic review and meta‐analysis

Carbone, Luigi; Trinchillo, Maria Giuseppina; Girolamo, Raffaella Di; Raffone, Antonio; Saccone, Gabriele; Iorio, Giuseppe Gabriele; Gabrielli, Olimpia; Maruotti, Giuseppe Maria

doi:10.1002/ijgo.14336

Cited by 29 publications

(22 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We showed that the vaccine was effective in generating a humoral immune response of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 IgG) levels in pregnant women [ 12 ]. Furthermore, a recent meta-analysis has compared pregnancy outcomes between vaccinated and non-vaccinated pregnant women and has shown no difference in the probability of having a small-for-gestational-age fetus and also showed reduced risk for premature delivery in vaccinated pregnant women compared with non-vaccinated pregnant women [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy

Toussia-Cohen

Yinon

Peretz-Machluf

et al. 2022

JCM

View full text Add to dashboard Cite

(1) Background: The adverse-effect profile and short-term obstetric and neonatal outcomes among pregnant women who were vaccinated with the BNT162b2 vaccine at any stage of pregnancy do not indicate any safety concerns. The vaccine is effective in generating a humoral immune response in pregnant women. (2) Objective: To determine the vaccine-induced immunity and adverse events associated with the third (booster) dose of the BNT162b2 vaccine compared to the first and second dose of the vaccine among pregnant women. (3) Study design: A prospective cohort study in a tertiary referral center comparing pregnant women who were vaccinated by the first and second dose of the BNT162b2 (Pfizer/BioNTech) vaccine to pregnant women vaccinated by a third (booster) dose, between January and November 2021. A digital questionnaire regarding adverse events was filled by both groups 2–4 weeks after vaccination. Blood samples were collected and tested for SARS-COV-2 IgG antibodies 28–32 days after the administration of the second or third BNT162b2 dose. (4) Results: Seventy-eight pregnant women who received the first and second doses of the vaccine were compared to eighty-four pregnant women who received the third dose of the vaccine. In terms of adverse events following vaccination, local rash/pain/swelling (93.6% vs. 72.6%, p < 0.001) was significantly less common after the third vaccination compared to after the second vaccination. Other adverse events, including early obstetric complications, did not differ between the two groups. SARS-CoV-2 IgG serum levels 28–32 days after the vaccination were significantly higher after the third vaccination compared to the second vaccination (1333.75 vs. 2177.93, respectively, p < 0.001). (5) Conclusion: This study confirms the safety regarding early adverse events and immunogenicity, and the lack of early obstetric complications of the BNT162b2 second- and third-dose vaccine in pregnant women. The third (booster) dose is effective in generating a stronger humoral immune response in pregnant women compared with the second dose.

show abstract

Section: Introductionmentioning

confidence: 99%

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy

Toussia-Cohen

Yinon

Peretz-Machluf

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…This result is similar to that of a previous report that showed the Safety of the COVID-19 vaccine and did not link it to an increased risk of gestational diabetes (21) . A systematic review could not prove any relationship between the COVID-19 vaccine and gestational diabetes (22) . This study showed that the COVID-19 vaccine caused neither polyhydramnios nor oligohydramnios.…”

Section: Discussionmentioning

confidence: 93%

COVID-19 Vaccine During Pregnancy and Perinatal Outcomes

Almutairi

Asiri

Alsuwaidan

et al. 2022

Preprint

View full text Add to dashboard Cite

Initially, there was little data on the safety of immunization against COVID-19 infection in pregnant women. However, previous studies revealed no safety concerns for pregnant women or newborns who received an mRNA COVID-19 vaccine during pregnancy. Therefore, this study aimed to investigate the effects of COVID-19 vaccination on perinatal outcomes. Methods: This cross-sectional study. It started from January 2022 to June 2022. The questionnaire was developed and validated by experts. This study included all women admitted to the postpartum ward who were more than 18 years old and had received the COVID-19 vaccine. The study excluded women without proof of their vaccination status or who could not complete the questionnaire. The primary outcome was the effect of COVID-19 vaccination on gestational age and birth weight. Results: A total of 365 participants. The mean gestational age of the unvaccinated women was 38.83 ± 1.62 weeks (p < 0.001), higher than that of vaccinated women (37.69 ± 2.9 weeks). However, the average birth weight for the unvaccinated women was 2.96 ± 0.4 kg (p = 0.89) and for vaccinated women (2.97 ± 0.66 kg). Conclusion: COVID-19 vaccination, regardless of the type of vaccine received before, during, or after pregnancy, is not associated with any unfavorable perinatal outcomes.

show abstract

“…This result is similar to that of a previous report that established the safety of the COVID-19 vaccine and did not link it to an increased risk of gestational diabetes [ 21 ]. A systematic review could not prove any relationship between the COVID-19 vaccine and gestational diabetes [ 22 ]. This study showed that the COVID-19 vaccine caused neither polyhydramnios nor oligohydramnios.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccine During Pregnancy and Perinatal Outcomes

Almutairi

Asiri

Alsuwaidan

et al. 2023

Cureus

View full text Add to dashboard Cite

Introduction When COVID-19 vaccination started, there was little data on the safety of immunization against COVID-19 infection in pregnant women. Previous studies revealed no safety concerns for pregnant women or newborns who received a messenger ribonucleic acid (mRNA) COVID-19 vaccine during pregnancy. This study aimed to investigate the effects of COVID-19 vaccination on pregnant women and on perinatal outcomes. Methods This cross-sectional study was conducted in a maternity hospital in King Saud Medical City. It started in January 2022 and ended in June 2022. The questionnaire was developed and validated by experts. This study included all women admitted to the postpartum ward who were more than 18 years old and had received the COVID-19 vaccine. The study excluded women who had no proof of their vaccination status or who could not complete the questionnaire. The primary outcome was the effect of COVID-19 vaccination on gestational age and birth weight. The secondary outcomes included the development of polyhydramnios, oligohydramnios, mode of delivery, Apgar score, postpartum hemorrhage, and neonatal intensive care unit admission. Results A total of 365 pregnant women participated in this study. The mean gestational age of the unvaccinated women was 38.83 ± 1.62 weeks, which was significantly (p < 0.001) higher than that of vaccinated women (37.69 ± 2.9 weeks). In addition, the average birth weight for the unvaccinated women was 2.96 ± 0.4 kg, which did not differ significantly (p = 0.89) from that of vaccinated women (2.97 ± 0.66 kg). Conclusion COVID-19 vaccination, regardless of the type of vaccine received before, during, or after pregnancy, is not associated with any unfavorable perinatal outcomes for pregnant women or neonates.

show abstract

COVID‐19 vaccine and pregnancy outcomes: A systematic review and meta‐analysis

Cited by 29 publications

References 61 publications

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy

Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy

COVID-19 Vaccine During Pregnancy and Perinatal Outcomes

COVID-19 Vaccine During Pregnancy and Perinatal Outcomes

Contact Info

Product

Resources

About